Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

November 01, 1999; 53 (8) Articles

Measuring quality of life in a way that is meaningful to stroke patients

Linda S. Williams, Morris Weinberger, Lisa E. Harris, José Biller
First published November 1, 1999, DOI: https://doi.org/10.1212/WNL.53.8.1839
Linda S. Williams
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Morris Weinberger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa E. Harris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José Biller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Measuring quality of life in a way that is meaningful to stroke patients
Linda S. Williams, Morris Weinberger, Lisa E. Harris, José Biller
Neurology Nov 1999, 53 (8) 1839; DOI: 10.1212/WNL.53.8.1839

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
3

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Objective: To identify predictors of poststroke quality of life.

Background: Health-related quality of life (HRQOL) measures assess the impact of disease on the physical, emotional, and social aspects of patients’ lives. Although HRQOL measures are used increasingly, factors associated with HRQOL poststroke and the ability of stroke-specific versus generic HRQOL measures to predict patient-reported HRQOL are not well known.

Methods: A total of 71 patients were evaluated 1 month postischemic stroke with a new stroke-specific HRQOL measure—the SS-QOL—and the SF-36, a generic HRQOL measure. Stroke severity, impairments, and functional limitations were also measured. Demographic variables and outcome measure scores were compared between patients rating their overall HRQOL the same as prestroke versus those with overall HRQOL worse than prestroke. Independent predictors of overall HRQOL were identified using multivariable modeling.

Results: Variables associated with better overall HRQOL were higher (better) SS-QOL and Barthel Index scores, and lower (better) NIH Stroke Scale and Beck Depression Inventory scores. Independent predictors of good overall HRQOL were the SS-QOL score (odds ratio [OR], 2.97; 95% CI, 1.3, 7.1; p = 0.01) and NIH Stroke Scale score (OR, 0.69; 95% CI, 0.47, 0.99; p = 0.05). Demographic factors and SF-36 scores were not associated with overall HRQOL ratings.

Conclusions: Stroke-specific quality of life score and patient impairments predict patient-reported overall health-related quality of life (HRQOL) poststroke. SF-36 scores were not associated with overall HRQOL ratings. Disease-specific HRQOL measures are more sensitive to meaningful changes in poststroke HRQOL and may thus aid in identifying specific aspects of poststroke function that clinicians and “trialists” can target to improve patients’ HRQOL after stroke.

Health-related quality of life (HRQOL) refers to the constellation of physical, psychological, and social aspects of life that may be affected by changes in health states.1-3 It is important to incorporate patient-centered outcomes like HRQOL into clinical measures so that the impact of disease on the patient as a whole can be understood and quantified.3-5 This concept is especially relevant in stroke, when patients have both a broad range of impairments and a wide spectrum of symptom severity.

HRQOL outcomes are incorporated increasingly as an outcome in clinical trials, but knowing whether the treatment really made a difference in patients’ HRQOL is often difficult. To date, most stroke trials have used generic HRQOL scales. Although generic HRQOL measures have the advantage of allowing comparisons of patients with different diseases, they are less sensitive for exploring the effects of particular impairments on HRQOL or for assessing response to treatment in an individual with a specific disease.5,6 In stroke research, the disadvantages of generic HRQOL measures are particularly apparent.7 One critical question in evaluating HRQOL outcomes in a clinical trial is whether aspects of patients’ lives that patients consider important have been measured.8 If a generic HRQOL measure does not assess hand dexterity, communication, or vision, then how can the effects of these common stroke impairments on HRQOL be measured? By this practical criterion, most generic HRQOL measures have questionable validity poststroke. Although disease-specific scales are designed to have superior content validity and improved sensitivity to change compared with generic scales, no direct comparison of generic and stroke-specific HRQOL measures has been reported previously.

Because of the problems using generic HRQOL measures in specific diseases, we developed recently the SS-QOL—a new stroke-specific quality of life measure.9 Content validity of SS-QOL items was established by developing items from interviews of stroke survivors. The original item pool was tested in a prospective cohort of ischemic stroke patients. The resulting 49-item version (SS-QOL, version 2.0) showed promising initial psychometric characteristics, with internal reliability of each individual domain ≥0.73 and no notable ceiling or floor effects.

The aims of this research are to use the SS-QOL to identify the predictors of poststroke HRQOL in patients with mild to moderate ischemic stroke and to compare the ability of the SS-QOL with that of a generic HRQOL scale for predicting overall HRQOL poststroke.

Methods.

Study cohort.

Patients older than 18 years with acute ischemic stroke were identified from three adult hospitals (a veterans administration hospital, a county hospital, and a tertiary referral hospital) to develop and to validate a new stroke-specific HRQOL measure, the SS-QOL. Because the primary aim in assembling the cohort was instrument development, patients were excluded if they met any of the following criteria: prior stroke with persistent deficit, intracerebral or subarachnoid hemorrhage, dysphasia at 1 month poststroke such that meaningful communication could not be established, and marked comorbidities likely to affect HRQOL concurrently (e.g., class III or IV heart failure, peritoneal or hemodialysis, preexisting musculoskeletal disease limiting physical function markedly, metastatic cancer, active psychiatric disease or dementia, and diagnosis of HIV infection or AIDS).

Study instruments and follow-up.

The following data were collected 1 month ± 1 week poststroke: demographic information, location and size of stroke, ischemic stroke subtype according to Trial of ORG-10172 in Acute Stroke Treatment (TOAST) criteria,10 and length of stay and discharge disposition. Initial stroke severity was determined retrospectively in a previously validated fashion with the Canadian Neurologic Scale.11 An interviewer administered the following measures in random order: the SS-QOL,9 the SF-36 (a generic HRQOL measure),12 and the Beck Depression Inventory (BDI; a depression symptom scale).13 Stroke-related impairments were measured with the NIH Stroke Scale (NIHSS),14 and disability was measured with the Barthel Index.15

The SS-QOL was developed using standard psychometric techniques from interviews with stroke survivors, and it includes 49 items encompassing 12 domains: energy, family roles, language, mobility, mood, personality, self-care, social roles, thinking, vision, upper extremity function, and work/productivity. Each item is ranked on a 5-point Likert scale, with higher scores indicating better function. Domain scores are unweighted averages of the items comprising that domain, and the summary SS-QOL score is an unweighted average of the 12 domain scores. In addition to the SS-QOL items, patients also rated independently each SS-QOL domain and their overall HRQOL compared with prestroke as the same, a little worse, or a lot worse. For this analysis, overall HRQOL was dichotomized (the same versus worse than prestroke HRQOL). Patients were considered depressed if their BDI score was ≥10.16

Analyses.

Demographic variables and SS-QOL, SF-36, NIHSS, and Barthel Index scores were compared in those with overall HRQOL the same and in those with overall HRQOL worse than prestroke using Student’s t-test or the chi square test. Logistic regression modeling with overall HRQOL as the dependent variable, and variables with p values <0.1 as independent variables, was used to identify the independent predictors of poststroke HRQOL. Interactions between candidate independent variables were considered in the model.

Results.

Between August 1, 1997, and June 1, 1998, 71 patients were enrolled in the study. The mean age of the subjects was 61 years, 63% were male, 25% were African–American, and 18% had no health insurance (table 1). Most patients had mild stroke with a mean Canadian Neurologic Scale score on admission of 9.2 ± 1.9 (SD; range, 2.0 to 11.5; best possible score, 11.5). NIHSS scores were ≥1 in 43% of patients, and the Barthel Indexes were ≥95 in 81% of patients. The mean SF-36 score was 56 ± 16, and the mean SS-QOL score was 3.8 ± 0.7. HRQOL was rated the same as prestroke by 48% of subjects. A total of 39% of the subjects met criteria for at least mild depression. By TOAST criteria, 51% had lacunar stroke, 61% had stroke ≤1 cm on CT or MRI, and 58% of strokes were in the deep gray or subcortical white matter.

View this table:
  • View inline
  • View popup
Table 1.

Cohort demographics and stroke data (n = 71)

Variables associated significantly with patients’ overall HRQOL rating were SS-QOL, NIHSS, and BDI scores (table 2). Age, gender, ethnicity, stroke size, and SF-36 scores were not associated with overall HRQOL rating. Multivariable modeling with NIHSS, Barthel Index, BDI, and SS-QOL scores as independent variables showed that the odds of HRQOL being the same as prestroke were associated with higher (better) SS-QOL scores (OR, 2.97; 95% CI, 1.3, 7.1) and lower (better) NIHSS scores (OR, 0.69; 95% CI, 0.47, 0.99; table 3). No significant interactions were seen between candidate variables.

View this table:
  • View inline
  • View popup
Table 2.

Demographic and outcome measure scores by overall HRQOL group

View this table:
  • View inline
  • View popup
Table 3.

Independent predictors of overall HRQOL the same as prestroke

To determine whether only a few specific domains of the SS-QOL were responsible for the overall HRQOL rating, domain scores were compared in the two overall HRQOL groups (table 4). Although all domains except upper extremity were either the same or higher in the group with better HRQOL, only the family roles domain was significantly different, with higher (better) scores in those with better overall HRQOL (mean score, 4.0 versus 3.4; p = 0.04).

View this table:
  • View inline
  • View popup
Table 4.

SS-QOL domain scores* by HRQOL group

Discussion.

In this sample of patients with mild to moderate ischemic stroke, the summary SS-QOL score was associated significantly with patient ratings of overall HRQOL 1 month poststroke. Of interest is that this association was not observed with the SF-36. In our patients, the SF-36 physical function and physical role scores did not exhibit a ceiling effect (scores were ≤51 in both groups), but rather failed to discriminate patient-reported differences in overall HRQOL. As in other conditions, generic HRQOL measures may be less sensitive to meaningful HRQOL changes after ischemic stroke because either the domains or the specific items lack relevance to stroke survivors7—a hypothesis supported by the inability of some SF-36 scale scores to discriminate markedly between the health status of patients with TIA and minor stroke.17

This increased sensitivity of stroke-specific measures has important implications for both the clinician and the “trialist.” Clinically, stroke-specific assessments can aid in identifying what is helping or hindering the patient’s overall function, allowing the clinician to target interventions that are patient and situation specific. For example, if a patient’s mood or energy score is low, then consideration of an antidepressant may be warranted, or if the upper extremity score is low, then referral to occupational therapy may be considered. In stroke trials, the benefit of a stroke-specific measure is that it can assess change across the spectrum of stroke symptoms and severity, thus allowing a broader range of stroke patients to be studied, requiring fewer subjects to detect differences, and providing a greater ability to detect differences that are truly meaningful to patients.

Prior studies of the predictors of generic HRQOL poststroke have used different HRQOL measures and a wide variety of candidate predictor variables in populations that sometimes included patients with TIA or hemorrhagic stroke types. Despite these difficulties, some variables associated frequently with impaired poststroke HRQOL include more impairments,18-20 functional disability,21-23 and depression.18,22,23 One reason that the SS-QOL may be most predictive of overall HRQOL ratings in our patients is that it incorporates a wide variety of impairments, disabilities, and handicaps, and thus has more explanatory power than an assessment of only one of these outcome categories. This limitation of single outcome measures is exemplified by the Barthel Index, which has a marked ceiling effect in patients with less severe stroke, as demonstrated in our cohort.

It is well-known that nonstroke-related depression may affect HRQOL more than other common chronic conditions.24-26 In our patients, depressive symptoms were associated with overall HRQOL in bivariate analyses, but were not associated independently with overall HRQOL. One potential explanation is that, although no significant interaction between SS-QOL and BDI scores were found, the inclusion of a mood domain in the overall SS-QOL score may already account for the effect of depressive symptoms on HRQOL. Some studies have reported that poststroke depression is more common in patients with more severe stroke.27-29 Even though our patients had mild to moderate stroke, a similar proportion (39%) were depressed 1 month poststroke, as in other hospital and community samples.30-32 Thus, our ability to assess depression as a potential independent predictor of HRQOL was not limited by a low rate of depression in our cohort.

Because the SS-QOL score was the strongest predictor of overall poststroke HRQOL, we were interested in knowing whether certain SS-QOL domains explained most of this association. We found only the family roles domain to be significantly different, however, with higher scores in those with better overall HRQOL. Although we cannot discount the potential impact of multiple tests, this finding may underscore the importance of assessing handicap after stroke, because difficulty in assuming prestroke family or social roles may influence strongly patients’ HRQOL. The finding that 10 of the 12 domain scores were higher (better) in those with better overall HRQOL supports both the construct of the SS-QOL as an HRQOL measure and the concept of poststroke HRQOL as more than just the sum of individual impairments or disabilities.20

This study has several important limitations. Because there is no established gold-standard HRQOL outcome measure in stroke, we used a single question about overall HRQOL as the dependent variable in our model. Although a single question would not be expected to be responsive to change, this type of measure can categorize successfully individual patients with various stroke outcomes.33 Additional construct validity of our single question is demonstrated by the observation that all outcome measures except the SF-36 had better scores in patients reporting better overall HRQOL. Other limitations are that the cohort is small, represents a relatively homogeneous group of stroke patients with mild to moderate stroke, and does not include patients with marked cognitive or language dysfunction. Until proxy measures of stroke-specific quality of life are validated, the effects of language and cognitive changes on stroke-specific HRQOL are difficult to assess. Because relatively few patients with severe stroke were studied, it may be that other variables are also associated with overall stroke-specific HRQOL in these patients. We are currently conducting a study to address this question.

The important consideration in choosing an HRQOL measure for stroke research is to define the primary research question. This usually leads to the selection of a generic HRQOL measure when the aim is to compare stroke patients with patients with other diseases, and also leads to the selection of a disease-specific measure when the aim is to assess therapeutic response or to identify specific predictors of poststroke HRQOL.34,35 Because even patients with mild to moderate stroke have a marked decrease in HRQOL poststroke, measures like the SS-QOL may be especially valuable because they are more sensitive than generic measures to meaningful changes in poststroke HRQOL. Ongoing research will serve to determine the clinically meaningful difference in SS-QOL scores for both research and clinical practice applications and to validate further the SS-QOL in other populations. This work will provide a better understanding of the factors associated with poststroke HRQOL and thus will aid in designing interventions aimed at improving patients’ HRQOL after ischemic stroke.

Acknowledgments

Supported by a Research Career Development award, Office of Research and Development, Health Services Research and Development, Department of Veterans Affairs (L.S.W.).

Footnotes

  • Performed in part at the Regenstrief Institute for Health Care.

  • Received April 29, 1999.
  • Accepted June 22, 1999.

References

  1. ↵
    Patrick DL, Bush JW, Chen MM. Toward an operational definition of health. J Health Soc Behav 1973;14:6–23.
    OpenUrlCrossRefPubMed
  2. Bergner M. Quality of life, health status and clinical research. Med Care 1989;27 (suppl):S148–S156.
    OpenUrlCrossRefPubMed
  3. ↵
    Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993;118:622–629.
    OpenUrlCrossRefPubMed
  4. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1995;334:835–839.
    OpenUrlCrossRefPubMed
  5. ↵
    Guyatt G, Feeny D, Patrick D. Issues in quality-of-life measurement in clinical trials. Control Clin Trials 1991;12:81S–90S.
    OpenUrlCrossRefPubMed
  6. ↵
    Berzon R, Hays RD, Shumaker SA. International use, application and performance of health-related quality of life instruments. Qual Life Res 1993;2:367–368.
    OpenUrlCrossRefPubMed
  7. ↵
    Williams LS. Health-related quality of life outcomes in stroke. Neuroepidemiology 1998;17:116–120.
    OpenUrlCrossRefPubMed
  8. ↵
    Guyatt GH, Naylor CD, Juniper E, Heyland DK, Jaeschke R, Cook DJ. Users’ guides to the medical literature. XII. How to use articles about health-related quality of life. JAMA 1997;277:1232–1237.
    OpenUrlCrossRefPubMed
  9. ↵
    Williams LS, Weinberger M, Harris LE, Clark DO, Biller J. Development of a stroke-specific quality of life (SS-QOL) scale. Stroke 1999;30:1362–1369.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Gordon DL, Bendixen BH, Adams HP Jr, Clarke W, Kappelle LJ, Woolson RF. Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke: implications for clinical trials. The TOAST investigators. Neurology 1993;43:1021–1027.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Goldstein LB, Chilukuri V. Retrospective assessment of initial stroke severity with the Canadian Neurologic Scale. Stroke 1997;28:1181–1184.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Ware JE, Sherbourne CD. The MOS 36-item short form health survey (SF-36) 1: conceptual framework and item selection. Med Care 1992;30:472–483.
    OpenUrl
  13. ↵
    Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–571.
  14. ↵
    Brott T, Adams HP Jr, Olinger CP, et al. Measurement of acute cerebral infarction: a clinical examination scale. Stroke 1989;20:864–870.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Mahoney FD, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965;14:61–63.
    OpenUrlPubMed
  16. ↵
    Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 1988;8:77–100.
  17. ↵
    Duncan PW, Samsa GP, Weinberger M, et al. Health status of individuals with mild stroke. Stroke 1997;28:740–745.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Jonkman EJ, de Weerd AW, Vrijens NL. Quality of life after a first ischemic stroke. Long-term developments and correlations with changes in neurological deficit, mood and cognitive impairment. Acta Neurol Scand 1998;98:169–175.
    OpenUrlPubMed
  19. de Haan R, Horn J, Limburg M, van der Meulen J, Bossuyt P. A comparison of five stroke scales with measures of disability, handicap, and quality of life. Stroke 1993;24:1178–1181.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    de Haan RJ, Limburg M, van der Meulen JHP, Jacobs HM, Aaronson NK. Quality of life after stroke: impact of stroke type and lesion location. Stroke 1995;226:402–408.
    OpenUrl
  21. ↵
    Nieme M, Laaksonen R, Kotila M, Waltimo O. Quality of life 4 years after stroke. Stroke 1988;19:1101–1107.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    King RB. Quality of life after stroke. Stroke 1996;27:1467–1472.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Dorman PJ, Waddell F, Slattery J, Dennis M, Sandercock P. Is the EuroQol a valid measure health-related quality of life after stroke? Stroke 1997;28:1876–1882.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders: results from the PRIME-MD 1000 study. JAMA 1995;274:1511–1517.
    OpenUrlCrossRefPubMed
  25. Hays RD, Wells KB, Sherbourne CD, Rogers W, Spritzer K. Functioning and well-being outcomes of patients with depression compared with chronic general medical illness. Arch Gen Psychiatry 1995;52:11–19.
    OpenUrlCrossRefPubMed
  26. ↵
    Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989;262:914–919.
    OpenUrlCrossRefPubMed
  27. ↵
    Pohjasvaara T, Leppavuori A, Siira I, Vataja R, Kaste M, Erkinjuntti T. Frequency and clinical determinants of poststroke depression. Stroke 1998;29:2311–2317.
    OpenUrlAbstract/FREE Full Text
  28. Sharpe M, Hawton K, Seagroatt V, et al. Depressive disorders in long-term survivors of stroke: associations with demographic and social factor, functional status, and brain lesion volume. Br J Psychiatry 1994;164:380–386.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Herrman N, Black SE, Lawrence J, Szekely C, Szalai JP. The Sunnybrook Stroke Study: a prospective study of depressive symptoms and functional outcomes. Stroke 1998;29:618–624.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Robinson RG, Price TR. Post-stroke depressive disorders: a follow-up study of 103 patients. Stroke 1982;13:635–641.
    OpenUrlAbstract/FREE Full Text
  31. Kotila M, Numminen H, Waltimo O, Kaste M. Depression after stroke: results of the FINNSTROKE study. Stroke 1998;29:368–372.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Burvill PW, Johnson GA, Jamrozik KD, Anderson CS, Stewart–Wynne EG, Chakera TM. Prevalence of depression after stroke: the Perth Community Stroke Study. Br J Psychiatry 1995;166:320–327.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Lindley R, Waddell F, Livingstone M, et al. Can simple questions assess outcome after stroke? Cerebrovasc Dis 1994;4:314–332.
    OpenUrlCrossRef
  34. ↵
    Aaronson NK. Quality of life assessment in clinical trials: methodologic issues. Control Clin Trials 1989;10:195S–208S.
    OpenUrlCrossRefPubMed
  35. ↵
    Hays RD, Anderson R, Revicki D. Psychometric considerations in evaluating health-related quality of life measures. Qual Life Res 1993;2:441–449.
    OpenUrlCrossRefPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Methods.
    • Results.
    • Discussion.
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Article
    Quality of life in patients with TIA and minor ischemic stroke
    Rajbeer S. Sangha, Fan Z. Caprio, Robert Askew et al.
    Neurology, November 04, 2015
  • Articles
    Patient-centered outcomes
    Translating clinical efficacy into benefits on health-related quality of life
    Deborah Miller, Richard A. Rudick, Michael Hutchinson et al.
    Neurology, April 26, 2010
  • Article
    MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS
    Shahram Majidi, Marie Luby, John K. Lynch et al.
    Neurology, September 13, 2019
  • Research
    Frequency of early rapid improvement in stroke severity during interfacility transfer
    Kori S. Zachrison, Thabele M. Leslie-Mazwi, Gregoire Boulouis et al.
    Neurology: Clinical Practice, May 08, 2019
Neurology: 100 (13)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise